Summary | |
---|---|
Symbol | PLD1 |
Name | phospholipase D1, phosphatidylcholine-specific |
Aliases | choline phosphatase 1; phosphatidylcholine-hydrolyzing phospholipase D1; hPLD1; PLD 1; Phospholipase D1 |
Chromosomal Location | 3q26 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cytoplasm, perinuclear region Endoplasmic reticulum membrane Lipid-anchor Cytoplasmic side Golgi apparatus membrane Lipid-anchor Cytoplasmic side Late endosome membrane Lipid-anchor Cytoplasmic side |
Domain |
PF00169 PH domain PF00614 Phospholipase D Active site motif PF13091 PLD-like domain PF00787 PX domain |
Function |
Implicated as a critical step in numerous cellular pathways, including signal transduction, membrane trafficking, and the regulation of mitosis. May be involved in the regulation of perinuclear intravesicular membrane traffic (By similarity). |
Biological Process |
GO:0006654 phosphatidic acid biosynthetic process GO:0007265 Ras protein signal transduction GO:0016042 lipid catabolic process GO:0030031 cell projection assembly GO:0030033 microvillus assembly GO:0032528 microvillus organization GO:0032530 regulation of microvillus organization GO:0032534 regulation of microvillus assembly GO:0046473 phosphatidic acid metabolic process GO:0048017 inositol lipid-mediated signaling GO:0060491 regulation of cell projection assembly |
Molecular Function |
GO:0004620 phospholipase activity GO:0004630 phospholipase D activity GO:0005543 phospholipid binding GO:0008081 phosphoric diester hydrolase activity GO:0016298 lipase activity GO:0035091 phosphatidylinositol binding GO:0042578 phosphoric ester hydrolase activity GO:0070290 N-acylphosphatidylethanolamine-specific phospholipase D activity |
Cellular Component |
GO:0005765 lysosomal membrane GO:0005770 late endosome GO:0010008 endosome membrane GO:0016324 apical plasma membrane GO:0030139 endocytic vesicle GO:0031902 late endosome membrane GO:0044440 endosomal part GO:0045177 apical part of cell GO:0098852 lytic vacuole membrane |
KEGG |
hsa04014 Ras signaling pathway hsa04024 cAMP signaling pathway hsa04071 Sphingolipid signaling pathway hsa04144 Endocytosis hsa04666 Fc gamma R-mediated phagocytosis hsa04724 Glutamatergic synapse hsa04912 GnRH signaling pathway hsa00564 Glycerophospholipid metabolism hsa00565 Ether lipid metabolism hsa01100 Metabolic pathways |
Reactome |
R-HSA-2029480: Fcgamma receptor (FCGR) dependent phagocytosis R-HSA-1483206: Glycerophospholipid biosynthesis R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-1430728: Metabolism R-HSA-556833: Metabolism of lipids and lipoproteins R-HSA-6798695: Neutrophil degranulation R-HSA-1483257: Phospholipid metabolism R-HSA-2029485: Role of phospholipids in phagocytosis R-HSA-1483166: Synthesis of PA R-HSA-1483148: Synthesis of PG |
Summary | |
---|---|
Symbol | PLD1 |
Name | phospholipase D1, phosphatidylcholine-specific |
Aliases | choline phosphatase 1; phosphatidylcholine-hydrolyzing phospholipase D1; hPLD1; PLD 1; Phospholipase D1 |
Chromosomal Location | 3q26 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between PLD1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between PLD1 and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | PLD1 |
Name | phospholipase D1, phosphatidylcholine-specific |
Aliases | choline phosphatase 1; phosphatidylcholine-hydrolyzing phospholipase D1; hPLD1; PLD 1; Phospholipase D1 |
Chromosomal Location | 3q26 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of PLD1 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | PLD1 |
Name | phospholipase D1, phosphatidylcholine-specific |
Aliases | choline phosphatase 1; phosphatidylcholine-hydrolyzing phospholipase D1; hPLD1; PLD 1; Phospholipase D1 |
Chromosomal Location | 3q26 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of PLD1 in various data sets.
|
Points in the above scatter plot represent the mutation difference of PLD1 in various data sets.
|
Summary | |
---|---|
Symbol | PLD1 |
Name | phospholipase D1, phosphatidylcholine-specific |
Aliases | choline phosphatase 1; phosphatidylcholine-hydrolyzing phospholipase D1; hPLD1; PLD 1; Phospholipase D1 |
Chromosomal Location | 3q26 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PLD1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | PLD1 |
Name | phospholipase D1, phosphatidylcholine-specific |
Aliases | choline phosphatase 1; phosphatidylcholine-hydrolyzing phospholipase D1; hPLD1; PLD 1; Phospholipase D1 |
Chromosomal Location | 3q26 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PLD1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PLD1. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | PLD1 |
Name | phospholipase D1, phosphatidylcholine-specific |
Aliases | choline phosphatase 1; phosphatidylcholine-hydrolyzing phospholipase D1; hPLD1; PLD 1; Phospholipase D1 |
Chromosomal Location | 3q26 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PLD1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | PLD1 |
Name | phospholipase D1, phosphatidylcholine-specific |
Aliases | choline phosphatase 1; phosphatidylcholine-hydrolyzing phospholipase D1; hPLD1; PLD 1; Phospholipase D1 |
Chromosomal Location | 3q26 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of PLD1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | PLD1 |
Name | phospholipase D1, phosphatidylcholine-specific |
Aliases | choline phosphatase 1; phosphatidylcholine-hydrolyzing phospholipase D1; hPLD1; PLD 1; Phospholipase D1 |
Chromosomal Location | 3q26 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between PLD1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | PLD1 |
Name | phospholipase D1, phosphatidylcholine-specific |
Aliases | choline phosphatase 1; phosphatidylcholine-hydrolyzing phospholipase D1; hPLD1; PLD 1; Phospholipase D1 |
Chromosomal Location | 3q26 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting PLD1 collected from DrugBank database. |
Details on drugs targeting PLD1.
|